Ginkgo Bioworks Divests Biosecurity Unit, Retains Minority Stake
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ginkgo Bioworks Holdings ( (DNA) ) has issued an update.
On February 26, 2026, Ginkgo Bioworks, Inc., a wholly owned subsidiary of Ginkgo Bioworks Holdings, Inc., agreed to transfer all equity interests of Ginkgo Biosecurity, LLC to Tower Biosecurity, Inc., effectively divesting substantially all of the parent company’s Biosecurity segment operations. In return, Ginkgo will receive common stock in Tower Biosecurity representing about 20% of the purchaser’s fully diluted equity, with closing expected in the first half of 2026 subject to customary conditions, signaling a shift in how Ginkgo participates in the biosecurity market while retaining a minority stake in the combined platform.
The transaction is structured to move Ginkgo’s biosecurity activities into Tower Biosecurity’s corporate structure, potentially altering Ginkgo’s operational footprint and cost base in that segment while preserving exposure to any future growth via its equity interest. For stakeholders, the deal suggests a strategic repositioning away from directly operating the Biosecurity unit toward a partnership and ownership model, which may impact how investors assess the company’s risk profile and focus areas within the broader synthetic biology and biosecurity landscape.
The most recent analyst rating on (DNA) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.
Spark’s Take on DNA Stock
According to Spark, TipRanks’ AI Analyst, DNA is a Neutral.
The score is held down primarily by weak financial performance (shrinking revenue, large net losses, and continued cash burn). Offsetting this are a more constructive earnings-call picture around cost discipline and liquidity, and a mostly neutral technical setup; valuation remains challenged due to negative earnings and no dividend support.
To see Spark’s full report on DNA stock, click here.
More about Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., through its subsidiaries, operates in the synthetic biology and bioengineering industry, developing and deploying biological technologies across multiple applications. The company has also built a dedicated Biosecurity segment focused on biosecurity-related operations and services, positioned at the intersection of biotechnology and public health risk management.
Average Trading Volume: 990,564
Technical Sentiment Signal: Sell
Current Market Cap: $536.8M
See more data about DNA stock on TipRanks’ Stock Analysis page.
